Immuneering Corporation Proceeds from Sale and Maturity of Marketable Securities
Immuneering Corporation (IMRX) reported Proceeds from Sale and Maturity of Marketable Securities of $31.50 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Investing Activities
us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities · last filed 2026-08-05
- Immuneering Corporation proceeds from sale and maturity of marketable securities for the quarter ending 2026-06-30 was $22.50M.
- Immuneering Corporation proceeds from sale and maturity of marketable securities for the quarter ending 2026-03-31 was $9.00M.
- Immuneering Corporation proceeds from sale and maturity of marketable securities for the quarter ending 2025-12-31 was $0.00, a 100.00% decline year-over-year.
- Immuneering Corporation proceeds from sale and maturity of marketable securities for the quarter ending 2025-09-30 was $0.00.
- Immuneering Corporation proceeds from sale and maturity of marketable securities for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- Immuneering Corporation proceeds from sale and maturity of marketable securities for fiscal 2024 was $31.93M, a 38.95% decline from fiscal 2023.
- Immuneering Corporation proceeds from sale and maturity of marketable securities for fiscal 2023 was $52.30M, a 43.57% decline from fiscal 2022.
- Immuneering Corporation proceeds from sale and maturity of marketable securities for fiscal 2022 was $92.68M.
| Period end | Proceeds from Sale and Maturity of Marketable Securities 3 month | Proceeds from Sale and Maturity of Marketable Securities 6 month | Proceeds from Sale and Maturity of Marketable Securities 9 month | Proceeds from Sale and Maturity of Marketable Securities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $22.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $31.50M 10-Q · filed 2026-08-05 | $31.50M derived: sum of 3 quarters · filed 2026-08-05 | $31.50M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $9.00M 10-Q · filed 2026-05-15 | $9.00M derived: sum of 2 quarters · filed 2026-05-15 | $9.00M derived: sum of 3 quarters · filed 2026-05-15 | $9.00M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-06 | $0.00 derived: sum of 2 quarters · filed 2026-03-06 | $0.00 derived: sum of 3 quarters · filed 2026-08-05 | $0.00 10-K · filed 2026-03-06 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $0.00 derived: sum of 2 quarters · filed 2026-08-05 | $0.00 10-Q · filed 2025-11-12 | $5.50M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $0.00 10-Q · filed 2026-08-05 | $5.50M derived: sum of 3 quarters · filed 2026-08-05 | $5.50M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $0.00 10-Q · filed 2026-05-15 | $5.50M derived: sum of 2 quarters · filed 2026-05-15 | $5.50M derived: sum of 3 quarters · filed 2026-05-15 | $10.50M derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | $5.50M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-06 | $5.50M derived: sum of 2 quarters · filed 2026-03-06 | $10.50M derived: sum of 3 quarters · filed 2026-03-06 | $31.93M 10-K · filed 2026-03-06 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $5.00M derived: sum of 2 quarters · filed 2025-11-12 | $26.43M 10-Q · filed 2025-11-12 | $45.48M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $5.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | $26.43M 10-Q · filed 2025-08-13 | $45.48M derived: sum of 3 quarters · filed 2025-08-13 | $50.48M derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | $21.43M 10-Q · filed 2025-05-05 | $40.48M derived: sum of 2 quarters · filed 2025-05-05 | $45.48M derived: sum of 3 quarters · filed 2025-05-05 | $54.73M derived: sum of 4 quarters · filed 2025-05-05 |
| 2023-12-31 | $19.05M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $24.05M derived: sum of 2 quarters · filed 2025-03-20 | $33.30M derived: sum of 3 quarters · filed 2025-03-20 | $52.30M 10-K · filed 2025-03-20 |
| 2023-09-30 | $5.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $14.25M derived: sum of 2 quarters · filed 2024-11-13 | $33.25M 10-Q · filed 2024-11-13 | $53.85M derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | $9.25M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $28.25M 10-Q · filed 2024-08-06 | $48.85M derived: sum of 3 quarters · filed 2024-08-06 | $68.10M derived: sum of 4 quarters · filed 2024-08-06 |
| 2023-03-31 | $19.00M 10-Q · filed 2024-05-07 | $39.60M derived: sum of 2 quarters · filed 2024-05-07 | $58.85M derived: sum of 3 quarters · filed 2024-05-07 | $91.18M derived: sum of 4 quarters · filed 2024-05-07 |
| 2022-12-31 | $20.60M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-01 | $39.85M derived: sum of 2 quarters · filed 2024-03-01 | $72.18M derived: sum of 3 quarters · filed 2024-03-01 | $92.68M 10-K · filed 2024-03-01 |
| 2022-09-30 | $19.25M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $51.58M derived: sum of 2 quarters · filed 2023-11-09 | $72.08M 10-Q · filed 2023-11-09 | |
| 2022-06-30 | $32.33M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $52.83M 10-Q · filed 2023-08-03 | ||
| 2022-03-31 | $20.50M 10-Q · filed 2023-05-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |